Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 16 clinical trials
None
Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)

This study will evaluate the safety, efficacy, and pharmacokinetics of posaconazole (POS) intravenous (IV) and oral formulations in pediatric participants 2 to <18 years of age with invasive

posaconazole
fungal infection
cancer
  • 18 views
  • 08 Dec, 2021
  • 29 locations
None
Azole-echinocandin Combination Therapy for Invasive Aspergillosis

The goals of this study are 3-fold: First, the main study and the primary endpoint will evaluate if the overall mortality can be decreased with initial azole-echinocandin combination therapy compared with triazole monotherapy in patients with IA and documented voriconazole susceptibility. Second, the study design described will also allow to …

  • 0 views
  • 16 Oct, 2021
  • 4 locations
None
A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection

This study will provide: (1) new insights in the prevalence of Aspergillus infection in children and adolescents with CF aged 8-17 yrs; (2) an in silico modelled dose of posaconazole for

posaconazole
respiratory symptom
sweat test
fibrosis
itraconazole
  • 10 views
  • 26 Jul, 2021
  • 31 locations
None
Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)

This study aims to estimate the pharmacokinetics (PK) of posaconazole (POS, MK-5592) intravenous (IV) and powder for oral suspension (PFS) formulations in pediatric participants <2 years of

  • 4 views
  • 08 Dec, 2021
  • 16 locations
None
Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia

The purpose of this study is to assess the safety, tolerability and clinical activity of the combination S65487 with azacitidine in patients with acute myeloid leukaemia.

  • 0 views
  • 13 May, 2021
  • 1 location
None
Prophylactic Anticoagulation for Catheter-related Thrombosis

The main objective of this study is to compare the efficacy and safety of aspirin, low molecule heparin and rivaroxaban for preventing catheter-related thrombosis in middle-to-high-risk ambulatory patients with cancer and implantable venous access ports.

  • 0 views
  • 25 Jan, 2021
  • 19 locations
None
Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants

The purpose of the study is to investigate the pharmacokinetics of oral dosage of Posaconazole which is routinely administered as a standard care prophylaxis for patients undergoing cancer

posaconazole
cancer
  • 0 views
  • 26 Jan, 2021
  • 1 location
None
Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole

) and acute leukemia) treated for the prevention of primary fungal infections with posaconazole. The aim is evaluate the composite end-point graft-versus-host disease-free, relapse-free survival

posaconazole
antifungal
cell transplantation
myelodysplastic syndromes
cyclophosphamide
  • 19 views
  • 23 Jan, 2021
None
PTX3-targeted Antifungal Prophylaxis

This is a prospective genetically-stratified randomized double-blind event-driven multicentre clinical trial to assess the efficacy of posaconazole-based antifungal prophylaxis allocation

posaconazole
leukemia
neutropenia
diflucan
mold
  • 31 views
  • 23 Jan, 2021
  • 5 locations
None
Pharmacokinetics Variability of Posaconazole (PCZ) and Its Glucuronide Metabolite During Induction and Consolidation Treatments in Patients With Acute Myeloid Leukemia (AML): a Covariate Analysis With the Tablets Formulation and Evaluation of the Potential Risk of Hepatotoxicity

Among its authorized indications, posaconazole (PCZ) is prescribed for prophylaxis in onco-hematology patients at high risk of invasive fungal infections. This azole antifungal has a low

induction chemotherapy
  • 0 views
  • 05 Aug, 2021
  • 1 location